ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
ODISSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY (ODISSEY-SCD
- Myocardial Infarction (MI)
- Sudden Cardiac Death Due to Cardiac Arrhythmia
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- University Hospital, Clermont-Ferrand
- Enrolment target
- 400
- Started
- 1 October 2026
- Main results due
- 1 July 2033
- Study sites
- 13
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 80 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Patients over 18 years of age * Hospitalized for acute STEMI within 6 months (Type 1 myocardial infarction according to ESC recommendations, Thygesen EHJ 2018). * Left ventricular ejection fraction between 35% and 50% at least 40 days after acute myocardial infarction (see above). * Under optimal tolerated medical treatment. * Covered by a social security scheme. * Legally competent to give voluntary informed consent to participate in the study. * Patient who will not participate in further studies involving an investigational drug or device until the end of the trial (i.e. 60 months). Participation in registries is authorized Exclusion Criteria: * Presence of a secondary prevention indication for implantation of an implantable automatic defibrillator (ICD) * Presence of a pacemaker * Administration of ventricular antiarrhythmic drugs other than beta-blockers (i.e. amiodarone, sotalol, flecainide) * Patients with systemic diseases (cancer, liver failure or end-stage renal disease) * Patients with assessed life expectancy \< 1 year. * Age \> 80 * Adult patient under legal protection (guardianship, curatorship or other legal protection measure) * The subject is pregnant or nursing or positive beta HCG for women of childbearing age * Patient participating in another clinical research protocol involving an investigational drug or device within the last 30 days (participation in a registry is permitted at the same time).
What this study is about
In the sponsor’s own words, from the registry.
Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant.
Assessing the risk of SCD in post-infarction patients is crucial to determining appropriate prevention strategies, such as implanting automatic implantable defibrillators (ICDs). Assessment tools are varied, but currently only left ventricular ejection fraction (LVEF) \< 35% is identified and validated. However, this risk stratification is unsatisfactory, particularly in view of SCD in patients with a history of myocardial infarction and a moderately impaired LVEF (between 35 and 50%). Although the initial treatment of myocardial infarction is essential for the patient's immediate survival, managing the risk of sudden death in the long term remains a major clinical challenge. A multiparametric approach is needed to optimize prognosis and prevent premature death in these patients.
Study sites(13)
CHU Amiens
Amiens, France
Not yet recruiting
CHU Brest
Brest, France
Not yet recruiting
CHU Caen
Caen, France
Not yet recruiting
CHU Clermont-Ferrand
Clermont-Ferrand, France
Not yet recruiting
HCL - Hôpital de la Croix-Rousse
Lyon, France
Not yet recruiting
HCL - Hôpital Pierre Wertheimer
Lyon, France
Not yet recruiting
CHU Nancy
Nancy, France
Not yet recruiting
CHU Nantes Hôpital Nord Laennec
Nantes, France
Recruiting
APHP - Hôpital européen Georges-Pompidou
Paris, France
Not yet recruiting
CHU de Poitiers
Poitiers, France
Not yet recruiting
CHU Saint Etienne
Saint-Etienne, France
Not yet recruiting
CHU Toulouse
Toulouse, France
Not yet recruiting
CH Vichy
Vichy, France
Not yet recruiting
Showing 13 of 13 sites. 1 of the 13 sites on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07545512. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me